Novartis completes acquisition of IFM Due to develop first-in-class STING antagonist program targeting innate immune system
Acquiring Company
Novartis
Acquired Company
IFM Due
Switzerland
BostonBiotechnologyHealth CarepharmaceuticalsBiotechnologyHealth CareTherapeuticsDescription
Novartis has announced the acquisition of IFM Due, a subsidiary of IFM Therapeutics, with a strategic aim to further develop the first-in-class STING antagonist program targeting the innate immune system. The acquisition enables Novartis to gain full rights to IFM Due's portfolio of STING antagonists and leverage its expertise in inflammation science to address major unmet patient needs.
Quick answer
Novartis is acquiring IFM Due, announced March 13, 2024. Novartis is based in Switzerland.
- How much did Novartis pay for IFM Due?
- The deal value was not disclosed.
- What does Novartis do?
- Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel.
- Where are Novartis and IFM Due based?
- Novartis is based in Switzerland. IFM Due is based in Boston, Massachusetts, United States.
- Who are the decision-makers at Novartis?
- Fundz holds 1 contact at Novartis. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in pharmaceuticals and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline (April 10, 2024)
- Johnson & Johnson (J&J) completes $12.5 Billion Acquisition of Shockwave Medical to Strengthen Cardiac Health Solutions, $13B (April 5, 2024)
- Juvisé Pharmaceuticals acquires rights to MS therapy Ponvory outside North America (April 2, 2024)
- Abbvie To Acquire Landos Biopharma, Further Strengthening Its Portfolio In Inflammatory And Autoimmune Diseases (March 25, 2024)
- Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction (March 25, 2024)
- Bristol Myers Squibb completes acquisition of Karuna Therapeutics, Inc. to strengthen its neuroscience portfolio (March 18, 2024)
Who to call at Novartis, and when
When Novartis changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Novartis raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Novartis, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Novartis. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Novartis makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired IFM Due?
IFM Due was acquired by Novartis, based in Switzerland. The deal was reported on March 13, 2024. Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel. Novartis is publicly traded (NVS) and operates in Biotechnology.
When did Novartis acquire IFM Due?
Novartis's acquisition of IFM Due was reported on March 13, 2024. Novartis has announced the acquisition of IFM Due, a subsidiary of IFM Therapeutics, with a strategic aim to further develop the first-in-class STING antagonist program targeting the innate immune system. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does IFM Due do?
IFM Due, a subsidiary of IFM Therapeutics, is a biopharmaceutical company that focuses on developing small-molecule, orally available drug candidates targeting aberrant inflammatory responses of the innate immune system triggered by the cGAS-STING pathway. It is privately held, operating in Biotechnology, and is based in Boston.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.